A new meta-analysis of trials evaluating aspirin for primary prevention of cardiovascular disease has found no overall benefit, with aspirin use associated with a lower risk of cardiovascular events but an increased risk of major bleeding, and no effect of aspirin on cancer risk.
However, there still appears to be some disagreement on how to apply these findings.
No comments:
Post a Comment